News Focus
News Focus
icon url

derkampfer

04/09/23 9:10 AM

#42 RE: jondoeuk #41

Don't need to convince us. We are fully invested and believers in both the INKmune NK cell therapy for certain cancers as well as XPro for AD and possibly others neuro inflammation sensitive diseases, including Parkinson’s.

Two robust programs and each have multi-billion value potential based on TAM

Exciting times.

GLTA longs
icon url

jondoeuk

03/29/24 8:01 PM

#46 RE: jondoeuk #41

''The third patient for the INKmune™ AML program in UK and EU has been enrolled and subsequent to their completion of follow-up, the company will wind down the AML program to focus resources on the prostate-cancer program and other solid tumors.'' https://www.globenewswire.com/news-release/2024/03/28/2854450/0/en/INmune-Bio-Inc-Announces-Year-End-2023-Results-and-Provides-a-Q4-Business-Update.html

Good luck to them in solid tumours!